A new study suggests that giving immunochemotherapy earlier in the day helps patients with an advanced type of lung cancer live longer.
Previous studies suggested that the body’s internal clock, the circadian rhythm, can influence how well immune checkpoint inhibitors work. These drugs help the immune system recognize and attack cancer cells by blocking tumors’ ability to shut those immune responses down.
In several cancers — such as kidney, liver, stomach, esophagus, and head and neck cancers, as well as melanoma — giving this treatment in the morning has been associated with better outcomes than giving it in the late afternoon or evening.
Now, the new study, published Dec. 8 in the journal Cancer, shows that the time of day a drug is delivered also affects extensive-stage small cell lung cancer (ES-SCLC) — a fast-growing cancer that is typically associated…




